• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Acumen Pharmaceuticals Inc (NQ: ABOS )

    3.215 +0.035 (+1.10%)
    Streaming Delayed Price Updated: 3:15 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 49,282
    Open 3.160
    Bid (Size) 3.210 (8)
    Ask (Size) 3.220 (18)
    Prev. Close 3.180
    Today's Range 3.150 - 3.245
    52wk Range 1.810 - 11.31
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -24.00%
    -24.00%
    1 Month
    -19.83%
    -19.83%
    3 Month
    -5.99%
    -5.99%
    6 Month
    +45.80%
    +45.80%
    1 Year
    -18.40%
    -18.40%

    More News

    Read More
    Acumen Pharmaceuticals's Earnings: A Preview
    Via Benzinga
    Acumen Pharmaceuticals's Earnings Outlook
    Via Benzinga
    ABOS Stock Earnings: Acumen Pharmaceuticals Misses EPS for Q4 2023
    Via InvestorPlace
    Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 26, 2024
    Via Benzinga
    Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot
    Via InvestorPlace
    3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom
    Via InvestorPlace
    Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Are You A Trader Or Investor: Biotech Momentum Is Picking Up
    Via Talk Markets
    Topics ETFs
    Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
    Via Investor's Business Daily
    Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Earnings Scheduled For November 13, 2023
    Via Benzinga
    Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures
    Via InvestorPlace
    3 Promising Biotech Stocks Flying Under the Radar
    Via InvestorPlace
    Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
    From Acumen Pharmaceuticals, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.